Your browser doesn't support javascript.
loading
Single institutional experience of peripheral applications of a liquid embolic agent: Ethylene Vinyl Alcohol Copolymer.
Salaskar, Abhijit L; Razjouyan, Faezeh; Cho, Alexander L; Sood, Rishi R; Akman, Andrew; Scher, Daniel; Venbrux, Anthony C; Sarin, Shawn N.
Afiliação
  • Salaskar AL; Division of Vascular and Interventional Radiology, George Washington University Hospital, Washington, DC, 20037, USA. abhijitlausalaskar@ymail.com.
  • Razjouyan F; Division of Vascular and Interventional Radiology, George Washington University Hospital, Washington, DC, 20037, USA.
  • Cho AL; Division of Vascular and Interventional Radiology, George Washington University Hospital, Washington, DC, 20037, USA.
  • Sood RR; Division of Vascular and Interventional Radiology, George Washington University Hospital, Washington, DC, 20037, USA.
  • Akman A; Division of Vascular and Interventional Radiology, George Washington University Hospital, Washington, DC, 20037, USA.
  • Scher D; Division of Vascular and Interventional Radiology, George Washington University Hospital, Washington, DC, 20037, USA.
  • Venbrux AC; Division of Vascular and Interventional Radiology, George Washington University Hospital, Washington, DC, 20037, USA.
  • Sarin SN; Division of Vascular and Interventional Radiology, George Washington University Hospital, Washington, DC, 20037, USA.
CVIR Endovasc ; 3(1): 38, 2020 Aug 02.
Article em En | MEDLINE | ID: mdl-32743749
ABSTRACT

OBJECTIVE:

To evaluate the safety and efficacy of ethylene vinyl alcohol (EVOH) copolymer for the treatment of a variety of peripheral vascular pathologies.

RESULTS:

Between October 2010 and October 2017, 43 patients who underwent total 54 EVOH embolization procedures for the treatment of peripheral vascular pathologies were included. The cases which involved the use of EVOH for the treatment of nonvascular, neurologic, ophthalmologic, otolaryngologic or head-neck pathologies were excluded. The demographic data, technical and clinical success rates, and procedure-related details and complications were obtained. The most common indications for EVOH embolization were type II endoleaks (n = 18) and peripheral arteriovenous malformations (n = 14). The majority of cases (62.5%) used EVOH without any adjunct embolic material. The results of this study showed 100% technical success rates and 89% clinical success rates. No events of nontarget embolization or other procedure-related complications were noted. The mortality & morbidity rates were 0%. The loss to follow up rate was 16% (9 /54). The mean follow-up period was 134 days (range, 30 to 522 days).

CONCLUSION:

The single institutional experience supports the safety and efficacy of EVOH embolization in the treatment of various peripheral vascular conditions.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2020 Tipo de documento: Article